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Abstract Insulin increased 2-deoxyglucose (2-DG) uptake via 
the translocation of glucose transporter (GLUT) 4 to the plasma 
membrane fraction in rat adipocytes. The stimulatory actions of 
insulin were accompanied by both an increase in the immuno-
reactive p85 subunit of phosphatidylinositol (PI) 3-kinase in the 
plasma membrane fractions and PI 3-kinase activation by 
tyrosine phosphorylation of the p85 subunit. The ß3-adrenoceptor 
agonist CL316243 (CL) suppressed all the insulin actions in 
adenosine deaminase (ADA)-treated cells, but was without effect 
in non-ADA-treated cells. The inhibitory effects of CL on GLUT 
4 translocation and PI 3-kinase activation were abolished by the 
addition of N6-phenylisopropyl adenosine. Cholera toxin treat-
ment, which markedly increased intracellular cAMP levels, 
suppressed increases in the levels of GLUT 4 and PI 3-kinase in 
the plasma membrane fractions in response to insulin. In 
addition, dibutyryl (Bt2) cAMP also impaired the activation of 
PI 3-kinase by insulin. These results indicated that CL 
suppressed insulin-stimulated glucose transport under conditions 
where cAMP levels were markedly increased ( ~ 12-fold). The 
inhibitory actions of PI 3-kinase activation by insulin were 
exerted even when cAMP, 8-bromo-cAMP, or Bt2 cAMP was 
added to immunoprecipitates of the p85 subunit of PI 3-kinase, 
after treating the cells with insulin. These results suggest that CL 
suppressed insulin-stimulated PI 3-kinase activity via a cAMP-
dependent mechanism, at least in part, direct cAMP action in 
ADA-treated adipocytes, by which PI 3-kinase activation was 
inhibited, resulting in the decrease in GLUT 4 translocation and 
subsequent 2-DG uptake in response to insulin. 
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1. Introduction 
The tyrosine kinase of the ß-subunits of the insulin receptor 
activated by insulin phosphorylates the tyrosine residues of 
insulin receptor substrate (IRS) 1, leading to the translocation 
of glucose transporter (GLUT) 4 to the plasma membranes 
and subsequent glucose transport [1,2]. It has been reported 
that glucagon [3], VIP [4], or catecholamines [5], which in-
crease adenylyl cyclase activity, suppress insulin-stimulated 
glucose transport , suggesting that the inhibitory actions are 
due to a decrease in insulin binding [6-8], insulin receptor 
tyrosine kinase activity [9,10], or the intrinsic activity of the 
glucose transporter by cAMP-dependent mechanisms [11-13]. 
It is, however, unclear by which mechanism c A M P impairs 
some intermediary pathway between those events. We demon-
strated that epinephrine, isoproterenol, glucagon, and A C T H 
were able to stimulate glucose uptake under normal incuba-
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tion conditions where c A M P levels were increased up to ~ 3-
fold [14]. 
Recently, it was demonstrated that phosphatidylinositol 
(PI) 3-kinase is involved in insulin-regulated movement of 
G L U T 4 to the plasma membranes in rat adipocytes [15,16] 
or 3T3-L1 adipocytes [17]. Therefore, insulin receptor activa-
tion caused the rapid delivery of IRS- l /PI 3-kinase complexes 
to intracellular membranes where 3'-phosphoinositides had 
accumulated and functioned in the membrane-associated 
events which accompanied the translocation of G L U T 4 to 
the plasma membrane. On the other hand, adrenoceptors 
(ARs) of the rat adipocytes are mainly ßi and ß3 types ac-
cording to pharmacological analysis [18,19]. Hence, it is pos-
sible that ß3-AR agonists affect insulin-stimulated glucose 
transport via PI 3-kinase activity. We investigated the role(s) 
of typical ß 3-ARs on PI 3-kinase activity and G L U T 4 trans-
location related to insulin-stimulated glucose transport using a 
selective ß3-agonist, CL316243 (CL) [20]. 
2. Materials and methods 
2.1. Materials 
The ß3-AR agonist CL and the cAMP assay kit were generously 
provided by Lederle Laboratories (USA) and by Yamasa Shoyu Co. 
(Japan), respectively. Anti-rabbit GLUT 4 polyclonal antibody (C-
terminal polypeptide) was a kind gift from Dr. O. Ezaki (National 
Institute of Nutrition, Japan). Collagenase type I was purchased from 
Worthington Biochemical Corp. (USA). 2-Deoxy-D-l,2-[3H]glucose 
([3H]2-DG) and horseradish peroxidase-linked anti-mouse IgG were 
from Amersham (Japan). Anti-mouse phosphotyrosine monoclonal 
antibodies and anti-rabbit p85 subunit of PI 3-kinase polyclonal anti-
bodies for both immunoblotting and immunoprecipitation were from 
Zymed Laboratory, Inc. (USA) and from Upstate Biotechnology, Inc. 
(USA), respectively. Cholera toxin (CTX) and phosphatidylinositol 
were from List Biological Laboratories, Inc. (USA) and Serdary Re-
search Laboratories (USA), respectively. The enhanced chemilumines-
cence system (ECL Western blotting detection kit) and protein G-
Sepharose 4 Fast Flow were from Amersham (USA) and Pharmacia 
(USA), respectively. Insulin, leupeptin, aprotinin, Rol724 (phospho-
diesterase inhibitor), adenosine deaminase (ADA), Nonidet (N) P-40, 
2-DG, phenylisopropyladenosine (PIA), cAMP, cGMP, AMP, GTP, 
bovine serum albumin (BSA, FFA free), 8-bromo-AMP, and phenyl-
methylsulfonylfluoride (PMSF) were all from Sigma Chemical Co. 
(USA). 8-Bromo-cAMP and dibutyryl (Bt2) cAMP were from Yama-
sa Shoyu Co. (Japan). 
2.2. Preparation of adipocytes 
White adipocytes were isolated from the epididymal adipose tissues 
of male Wistar rats weighing 200-300 g by the collagenase digestion 
method as described elsewhere [21]. 
2.3. Measurement of glucose transport activity 
Isolated adipocytes were preincubated with various agents and fur-
ther incubated for 3 min with 0.2 mM [3H]2-DG in Krebs-Ringer 
bicarbonate buffer (pH 7.4) containing 3% BSA under an atmosphere 
of 95% 0 2 -5% C0 2 . 2-DG uptake was measured as described previ-
ously [21]. 
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2.4. Measurement of cAMP accumulation 
Isolated adipocytes were incubated with various agents for 10 min 
in Krebs-Ringer-HEPES buffer (pH 7.4) containing 3% BSA and 0.3 
mM Rol724. cAMP accumulation was measured by radioimmuno-
assay as described previously [22], 
2.5. The measurement of translocation of GLUT 4 and PI 3-kinase 
to plasma membrane fractions 
Isolated adipocytes were incubated with various agents. The cells 
were immediately separated from the medium by centrifugation. Cells 
were washed with buffer A (20 mM HEPES, pH 7.4, 0.25 M sucrose, 
1 mM EDTA, 1 mM PMSF, 5 |J,g/ml leupeptin, and 10 |J.g/ml apro-
tinin) and suspended in buffer A. Cell suspensions were homogenized 
in a Dounce homogenizer and centrifuged for 5 min at 3000 Xg. The 
supernatant was centrifuged for 20 min at 15 000Xg. Plasma mem-
brane fractions were used for immunological detection of GLUT 4 
proteins and p85 of PI 3-kinase. 
2.6. Immunoprecipitation andlor Western blot analysis 
Plasma membrane fractions prepared as described above were lysed 
in lysis buffer B (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% NP-40, 0.1 mM Na3V04 , 0.25% Na-deoxycholate, 1 mM 
PMSF, 10 mM NaF, 10 (ig/ml leupeptin, and 10 ug/ml aprotinin). 
Lysates were immunoprecipitated with p85 of PI 3-kinase antibody 
preadsorbed on protein G-Sepharose beads. Lysates or immune com-
plexes were subjected to 10% SDS-PAGE, after which the proteins 
were transferred to Immobilon-P filters. The filters were incubated 
with the appropriate antibody. Blots were developed using the ECL 
system employing horseradish peroxidase-linked anti-mouse IgG as 
described elsewhere [23,24]. 
2.7. Measurement of PI 3-kinase activity using immunoprecipitates 
for p85 antibody 
Isolated adipocytes were incubated with various agents. The cells 
were separated from the medium by centrifugation and lysed in chilled 
buffer (pH 7.4) containing 0.25 M sucrose, 50 mM HEPES, 150 mM 
NaCl, 1% NP-40, 10 mM EDTA, 10 mM Na 4P 20 7 , 10 mM NaF, 2 
mM Na3V04 , and 0.5 mM PMSF. After centrifugation at 15000Xg 
for 20 min, the supernatants were immunoprecipitated with p85 anti-
body, followed by protein G-Sepharose. The immunoprecipitates were 
used for the PI 3-kinase assay as described elsewhere [25], 
The quantitativeness of the relative intensities on autoradiograms 
was analyzed on a Macintosh computer using the NIH Image pro-
gram (developed at the U.S. National Institutes of Health and avail-
able from the Internet by anonymous FTP from zippy.nimh.nih.gov 
or on floppy disk from the National Technical Information Service, 
Springfield, VA, part number PB95-500195GEI). 
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Fig. 1. Effects of CL on cAMP accumulation and on insulin-stimu-
lated 2-DG uptake. Adipocytes were preincubated for 30 min in the 
presence (o) or absence (•) of ADA (2 U/ml). A: Each cell suspen-
sion was incubated with the indicated concentrations of CL for 10 
min. The amount of cAMP accumulation was determined. B: Each 
cell suspension was further preincubated with the indicated concen-
trations of CL in combination with insulin (70 nM) for 30 min (20 
min in the case of insulin) and incubated with 0.2 mM [3H]2-DG. 
2-DG uptake was determined. 
Fig. 2. Effects of CL and CTX on insulin-stimulated GLUT 4 trans-
location. Adipocytes were preincubated for 30 min in the presence 
or absence of ADA (2 U/ml) (A) or CTX (10 ug/ml) (B). Each cell 
suspension was incubated with various agonists for 20 min. Plasma 
membrane fractions were prepared and GLUT 4 proteins were de-
tected by immunoblotting with GLUT 4 antibodies. Insulin (70 
nM); CL (0.1 uM); PIA (10 |xM). 
2.8. Protein assay 
Protein was assayed by Bradford's method [26]. 
3. Results 
3.1. Effects of CL and CTX on cAMP accumulation and 
insulin-stimulated 2-DG uptake 
The effects of the ßß-agonist CL on cAMP accumulation 
and insulin-stimulated 2-DG uptake were examined in ADA-
treated and non-treated cells (Fig. 1A,B). CL slightly in-
creased cAMP levels ( ~ 3-fold), but did not affect insulin-
stimulated 2-DG uptake in non-ADA-treated cells. In the 
ADA-treated cells, CL markedly increased cAMP levels 
( ~ 12-fold) and suppressed insulin-stimulated 2-DG uptake 
dose-dependently. A rapid appearance of GLUT 4 in the 
plasma membranes in response to insulin occurred, leading 
to the increase in glucose uptake [27,28]. Hence, the effects 
of CL on GLUT 4 levels increased by insulin were examined 
by immunoblotting the GLUT 4 protein in the plasma mem-
brane fractions (Fig. 2). Insulin increased the level of GLUT 4 
protein in the plasma membrane fractions and the increase 
was completely abolished by CL in the ADA-treated cells. 
ADA treatment itself hardly attenuated the actions of insulin. 
The inhibitory action by CL was abolished by the addition of 
Fig. 3. Effects of CL and CTX on the p85 subunit of PI 3-kinase in 
the plasma membrane fractions. Adipocytes were preincubated for 
30 min in the presence or absence of ADA (2 U/ml) (A) or CTX 
(10 (ig/ml) (B). Each cell suspension was incubated with various ag-
onists for 20 min. Plasma membrane fractions were prepared and 
p85 proteins were detected by immunoblotting with p85 subunit 
antibodies. Insulin (70 nM); CL (0.1 uM). 
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Fig. 4. Effects of CL on insulin-stimulated tyrosine phosphorylation 
of the p85 subunit of PI 3-kinase. Adipocytes were preincubated for 
30 min in the presence or absence of ADA (2 U/ml). Each cell sus-
pension was incubated with insulin (70 nM) with or without CL 
(0.1 ixM) for 20 min. Cell lysates were subjected to immunoprecipi-
tation with the p85 subunit antibody and analyzed by SDS-PAGE. 
Phosphotyrosine-containing proteins were detected by immunoblot-
ting with a phosphotyrosine antibody. 
Fig. 6. Effects of cAMP on PI 3-kinase activity from insulin-stimu-
lated adipocytes. Adipocytes were incubated with or without insulin 
(70 nM). Thereafter, PI 3-kinase activities were determined in the 
presence of the indicated concentrations of cAMP using immuno-
precipitates for the p85 subunit. 
the non-hydrolyzable adenosine analogue PIA (Fig. 2A). CTX 
[29], which caused a marked increase in cAMP levels via the 
ADP-ribosylation of Gsa, also impaired insulin-induced in-
creases in GLUT 4 levels. The basal level of GLUT 4 was 
not affected by CTX treatment (Fig. 2B). These results indi-
cate that CL suppressed insulin-stimulated glucose transport 
via the inhibition of GLUT 4 translocation induced by a 
marked increase in the cAMP levels with ADA or CTX treat-
ment. 
3.2. Effects of CL and CTX on PI 3-kinase 
The effects of CL and CTX on the amount of PI 3-kinase 
were examined by immunoblotting p85 protein in the plasma 
membrane fractions (Fig. 3). Insulin caused an increase in p85 
proteins and the increase was not affected by CL. In ADA-
treated cells, CL abolished the increase in the p85 protein 
induced by insulin (Fig. 3A). CTX treatment also attenuated 
the increase in the p85 protein, but did not bring about a 
significant change in the basal p85 level (Fig. 3B). Effects of 
CL on insulin-stimulated tyrosine phosphorylation of the p85 
were examined by immunoblotting with an anti-p85 antibody 
and an anti-phosphotyrosine antibody (Fig. 4). Insulin caused 
tyrosine phosphorylation of p85 and CL was without any 
effect on tyrosine phosphorylation. In contrast, in ADA-
treated cells, CL greatly inhibited the tyrosine phosphoryla-
tion induced by insulin. 
3.3. Effects of CL and Bti cAMP on insulin-stimulated PI 
3-kinase activity 
To test whether the inhibitory effect of CL on insulin-stimu-
lated tyrosine phosphorylation of p85 leads to the suppression 
of PI 3-kinase activation, PI 3-kinase activity was assessed 
using the immunoprecipitates of p85 (Fig. 5A). Insulin greatly 
activated PI 3-kinase. CL inhibited insulin-stimulated PI 3-
kinase in ADA-treated cells. The inhibitory action of CL 
was abolished by the addition of PIA. Neither PIA nor 
ADA treatment affected basal and insulin-stimulated PI 3-
kinase activities. Bt2 cAMP also suppressed insulin-stimulated 
PI 3-kinase activity and had little effect on the basal PI 3-
kinase activity (Fig. 5B). These findings suggest that a marked 
increase in the cAMP level suppressed insulin-stimulated PI 3-
_ 400-
Fig. 5. Effects of CL and Bt2 cAMP on insulin-stimulated PI 3-kin-
ase activity. Adipocytes were preincubated for 30 min in the pres-
ence or absence of ADA (2 U/ml). Each cell suspension was incu-
bated with or without insulin (70 nM) with or without CL (0.1 
uJVI), PIA (10 uM) (A), or Bt2 cAMP (0.2 mM) (B). PI 3-kinase ac-
tivities were determined using immunoprecipitates of the p85 sub-
unit. 
Fig. 7. Effects of various nucleotides on PI 3-kinase activity from 
insulin-stimulated adipocytes. Adipocytes were incubated with or 
without insulin (70 nM). Thereafter, PI 3-kinase activities were de-
termined in the presence of various nucleotides at 100 uM using im-
munoprecipitates for the p85 subunit. Data represent means ± S.D. 
of four experiments. *P<0.05 and "P<0.01 compared with insu-
lin. 
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kinase activity, resulting in the suppression of GLUT 4 trans-
location and subsequent 2-DG uptake. 
3.4. The inhibitory effect ofcAMP on PI 3-kinase activity 
To determine the mechanism responsible for the inhibition 
of insulin-induced PI 3-kinase activation by Bt2 cAMP, cAMP 
was directly added to the immunoprecipitates of p85 subunit 
activated by insulin, and PI 3-kinase activity was assessed. 
cAMP had little effect on basal PI 3-kinase activity and in-
hibited insulin-stimulated PI 3-kinase activity in a concentra-
tion-dependent manner (Fig. 6). Direct effects of other nucleo-
tides on insulin-stimulated PI 3-kinase were also observed. 
Addition of Bt2 cAMP or 8-bromo-cAMP suppressed the in-
sulin-stimulated PI 3-kinase similar to cAMP, whereas 8-bro-
mo-AMP, cGMP, AMP, and GTP had no effect (Fig. 7). 
4. Discussion 
In rat adipocytes, the ß3-AR agonist CL caused a slight 
increase ( ~ 3-fold) in cAMP levels with no ADA treatment, 
but was without effect on insulin-stimulated 2-DG uptake. In 
contrast, CL caused marked cAMP accumulation ( ~ 12-fold) 
with ADA treatment and suppressed insulin-stimulated 2-DG 
uptake. These results indicate that the suppression of insulin-
stimulated 2-DG uptake by CL is dependent on the elimina-
tion of adenosine in the incubation medium. Insulin stimu-
lates glucose transport by translocation of mainly GLUT 4, 
but also, to a lesser extent, GLUT 1 [30], from the low density 
microsomes to the plasma membranes [27,28]. We also ob-
served similar results (data not shown). Western blotting ex-
periments with an antibody for GLUT 4 showed that the 
increase in the GLUT 4 protein in the plasma membrane 
fractions in response to insulin was not affected by CL in 
the absence of ADA and was abolished by CL in the presence 
of ADA, but was restored by further additions of PIA. CTX 
treatment, which induced a marked increase in cAMP levels in 
the absence of ADA, also suppressed the increase in GLUT 4 
protein in the plasma membrane fractions induced by insulin. 
These results indicate that marked cAMP accumulation inhib-
its GLUT 4 translocation to the plasma membranes induced 
by insulin. 
Insulin activates PI 3-kinase. This activation is needed to 
provoke GLUT 4-mediated glucose transport by insulin [25]. 
We showed that insulin-stimulated PI 3-kinase activities meas-
ured in the immunoprecipitates with p85 antibodies were in-
hibited by CL and the inhibition was abolished by further 
additions of PIA in the presence of ADA. Binding of tyro-
syl-phosphorylated IRS-1 by insulin receptor tyrosine kinase 
to the p85 subunit of PI 3-kinase in response to insulin occurs 
and leads to the phosphorylation of the subunit [25]. There-
fore, insulin stimulation is accompanied by translocation of 
the enzyme to the plasma membranes and tyrosine phosphor-
ylation of the p85 protein [15,17]. In fact, Western blotting 
experiments with an antibody for p85 showed that insulin 
increased the amount of p85 protein in the plasma membrane 
fractions, and CL in the presence of ADA and CTX treatment 
suppressed this increase in the p85 protein. Furthermore, in-
sulin increased an immunoreactive tyrosine-phosphorylated 
p85 protein, and the increase in the phospho-p85 protein 
was suppressed by CL in the presence of ADA. Heller-Harri-
son et al. [31] demonstrated that insulin directs the association 
of PI 3-kinase with GLUT 4-containing vesicles in rat adipo-
cytes. Our results suggest that the inhibitory effect of CL on 
insulin-stimulated 2-DG uptake is mediated via cAMP-de-
pendent mechanisms by which the appearance of PI 3-kinase 
on the cell surface, tyrosine-phosphorylation of p85, and sub-
sequent GLUT 4 translocation to the plasma membrane frac-
tions were inhibited. 
On the other hand, it was shown that high concentrations 
of cAMP, 8-bromo-cAMP, and Bt2 cAMP, but not other 
nucleotides directly inhibited PI 3-kinase activity in immuno-
precipitates of p85 prepared from insulin-stimulated cells. Re-
cently, it was reported that Bt2 cAMP directly binds to GLUT 
4, resulting in the inhibition of glucose transport [13]. It raises 
the possibility that cAMP has, at least in part, a direct effect 
on PI 3-kinase besides the cAMP-dependent mechanism in-
volved in insulin-regulated movement of PI 3-kinase to the 
plasma membrane. It would be interesting to study the mech-
anism of a decrease in PI 3-kinase activity via the direct ac-
tion^) of cyclic nucleotides in the signaling pathway(s) of 
insulin-stimulated glucose transport. 
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